Survey of oncologists finds knowledge gap on medical marijuana
As more states legalize medical marijuana, two key groups — researchers whose job is it to understand its benefits and drawbacks, and physicians charged with advising potential users — are struggling to catch up with policymakers.
Ilana Braun, an assistant professor of psychiatry at Harvard Medical School and chief of the division of adult psychosocial oncology at the Dana-Farber Cancer Institute, led a survey of cancer physicians around the country, exploring their attitudes and actions on medical marijuana.
The survey was sent to 400 oncologists, with a 63 percent response rate. We asked Braun to outline her findings, which were published last month in the Journal of Clinical Oncology.
Stories you may be interested in
Arfinn Med Patient Site
We get a lot of interest from patients asking about efficacy data for medical marijuana on a number of conditions. Though we are primarily an electronic medical record (EMR) company focussing on the cannabis industry and other complimentary or alternative therapies, our primary focus is better quality care for patients. So with that being said,…
Read More 
Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease
A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More 
Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders
Report of the Guideline Development Subcommittee of the American Academy of Neurology: We performed a systematic review of medical marijuana (1948–November 2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We graded the studies according to the American Academy of Neurology classification scheme for therapeutic articles. Read the full…
Read More 
Medical marijuana users tell their stories to Medical Cannabis Study Commission
Thursday, the Medical Cannabis Study Commission held its third meeting. The Commission has been tasked with presenting a policy recommendation to the legislature on exactly what the best medical marijuana bill should look like. The Commission held a public hearing in which a number of medical marijuana users claimed that the drug has benefitted them.…
Read More 
Thanks to the Farm Bill, Hemp Is Legal. Here’s What It Means for CBD.
On Tuesday, the Senate voted to approve a new an $867 billion farm bill, and on Wednesday, it passed in Congress. While the bill has plenty of positive merits, the one people are perhaps most excited about is the fact that it will legalize the production, sale, and distribution of industrial hemp at a federal…
Read More 
Scientists Discover Two New Cannabinoids
The plant Cannabis sativa produces more than 400 chemicals, but only one, THC, gets you high. Or so it seems. A group of Italian researchers announced on December 30th the discovery of two new cannabinoids, chemicals produced by weed like THC and CBD. The first, tetrahydrocannabiphorol (THCP), is allegedly 30 times more potent than THC, they claim.…
Read More